journal
MENU ▼
Read by QxMD icon Read
search

Clinical Colorectal Cancer

journal
https://www.readbyqxmd.com/read/28865674/tumor-regression-grade-after-neoadjuvant-chemoradiation-and-surgery-for-low-rectal-cancer-evaluated-by-multiple-correspondence-analysis-ten-years-as-minimum-follow-up
#1
Raffaello Mancini, Giada Pattaro, Maria Grazia Diodoro, Isabella Sperduti, Carlo Garufi, Vittoria Stigliano, Pasquale Perri, Gian Luca Grazi, Maurizio Cosimelli
BACKGROUND: The role of Mandard's tumor regression grade (TRG) classification is still controversial in defining the prognostic role of patients who have undergone neoadjuvant chemoradiation (CRT) and total mesorectal excision. The present study evaluated multiple correspondence analysis (MCA) as a tool to better cluster variables, including TRG, for a homogeneous prognosis. PATIENTS AND METHODS: A total of 174 patients with a minimum follow-up period of 10 years were stratified into 2 groups: group A (TRG 1-3) and group B (TRG 4-5) using Mandard's classification...
August 9, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28284574/comparison-of-5-fu-based-and-capecitabine-based-neoadjuvant-chemoradiotherapy-in-patients-with-rectal-cancer-a-meta-analysis
#2
Xiang-Cai Zou, Qi-Wen Wang, Ji-Min Zhang
INTRODUCTION: The inconvenience of using infusion therapies resulted in the development of capecitabine (CA), an oral fluoropyrimidine. In this meta-analysis, we evaluated 10 studies that compared the efficacy and safety of an oral CA-based regimen with those of a continuous infusion 5-fluorouracil (5-FU) regimen for neoadjuvant chemoradiotherapy in patients with rectal cancer. MATERIALS AND METHODS: The databases searched included Medline, Cochrane, EMBASE, and Google Scholar (until August 31, 2016)...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28242162/molecular-screening-for-lynch-syndrome-in-young-patients-with-colorectal-adenomas
#3
Robin B Mendelsohn, Keri Herzog, Jinru Shia, Nadiyah Rahaman, Zsofia K Stadler, Moshe Shike
BACKGROUND: The frequency of mismatch repair (MMR) deficiency (dMMR) in patients < 50 years with adenomas without a known germline mutation is unknown. Our aim was to define the frequency of dMMRs in adenomas from patients aged < 50 years. PATIENTS AND METHODS: We identified all patients aged 18 to 49 years who had undergone colonoscopy at Memorial Sloan Kettering Cancer Center from 2008 to 2013 and were identified as having tubular, villous, or tubulovillous adenomas on pathology...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28223103/her2-amplification-and-cetuximab-efficacy-in-patients-with-metastatic-colorectal-cancer-harboring-wild-type-ras-and-braf
#4
Jae Ho Jeong, Jihun Kim, Yong Sang Hong, Dalyong Kim, Jeong Eun Kim, Sun Young Kim, Kyu-Pyo Kim, Young-Kwang Yoon, Deokhoon Kim, Sung-Min Chun, Yangsoon Park, Se Jin Jang, Tae Won Kim
BACKGROUND: Cetuximab has shown clinical benefit in patients with metastatic colorectal cancer (mCRC) harboring wild-type RAS. Human epidermal growth factor receptor 2 (HER2) amplification may be a mechanism of cetuximab resistance. We evaluated the association between HER2 amplification and cetuximab efficacy in patients with mCRC harboring wild-type RAS and BRAF. PATIENTS AND METHODS: Between December 2003 and June 2013, we identified 142 patients with mCRC whose tumors harbored both wild-type exons 2, 3, and 4 in KRAS and NRAS, and wild-type exon 15 in BRAF using high throughput sequencing (OncoMap version 4...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28216247/oncologic-outcomes-of-oral-adjuvant-chemotherapy-regimens-in-stage-iii-colon-cancer-tegafur-uracil-plus-leucovorin-versus-capecitabine
#5
Jo Tashiro, Shigeki Yamaguchi, Toshimasa Ishii, Hiroka Kondo, Kiyoka Hara, Hiroki Shimizu, Kenichi Takemoto, Asami Suzuki
INTRODUCTION: Although several major trials of treatment for stage III colon cancer have been reported, no study has compared oral adjuvant chemotherapy regimens using tegafur-uracil in combination with leucovorin (UFT/LV) and capecitabine (CAPE) alone. This study compared the oncologic outcomes of treatment with these 2 oral regimens. PATIENTS AND METHODS: Records of patients with stage III colon cancer who underwent curative surgery and adjuvant chemotherapy from April 2007 and September 2014 were retrospectively reviewed...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28216246/effect-of-kras-and-braf-mutations-on-survival-of-metastatic-colorectal-cancer-after-liver-resection-a-systematic-review-and-meta-analysis
#6
Federica Tosi, Elena Magni, Alessio Amatu, Gianluca Mauri, Katia Bencardino, Mauro Truini, Silvio Veronese, Luciano De Carlis, Giovanni Ferrari, Michele Nichelatti, Andrea Sartore-Bianchi, Salvatore Siena
BACKGROUND: The purpose of the study was to evaluate whether the mutational status of Kirsten rat sarcoma viral oncogene homolog (KRAS) or b-viral oncogene homolog B1 (BRAF) could be an independent prognostic factor in the subset of patients with colorectal cancer liver metastases (CRLM) who undergo complete liver resection. MATERIALS AND METHODS: A systematic literature review was performed to identify articles reporting relapse-free survival (RFS) and/or overall survival (OS) of patients who underwent complete liver resection for CRLM, stratified according to KRAS and BRAF mutational status...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28209483/a-new-size-based-platform-for-circulating-tumor-cell-detection-in-colorectal-cancer-patients
#7
Bo Young Oh, Jhingook Kim, Woo Yong Lee, Hee Cheol Kim
BACKGROUND: Circulating tumor cells (CTCs) might play a significant role in cancer progression and metastasis. However, the ability to detect CTCs is limited, especially in cells undergoing epithelial-mesenchymal transition. In this study, we evaluated a new size-based CTC detection platform and its clinical efficacy in colorectal cancer. PATIENTS AND METHODS: Blood samples were obtained from 76 patients with colorectal cancer and 20 healthy control subjects for CTC analysis...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28209482/effectiveness-of-a-tailored-anterior-saturation-band-in-the-improvement-of-the-image-quality-of%C3%A2-pelvic-magnetic-resonance-for-assessing-rectal%C3%A2-cancer
#8
Chen-Chang Lee, Po-Chou Chen, Hong-Hwa Chen, Chung-Cheng Huang, Li-Han Lin, Shu-Hang Ng, Min-Chi Chen, Sheung-Fat Ko
PURPOSE: We sought to test the effectiveness of the application of a tailored anterior saturation band (ASB) to improve the image quality of pelvic magnetic resonance imaging (MRI) for assessing rectal cancer. METHODS: A total of 165 patients with MRI assessment of rectal cancer between 2013 and 2015 were included. The image quality scores (4-point scale: 1, nondiagnostic through 4, excellent) of MRI without and with tailored ASBs were compared. Sensitivity, specificity, positive and negative predictive values, and accuracy of pelvic MRIs with and without a tailored ASB for T-staging in 65 patients with direct surgery and 67 patients with chemoradiotherapy before surgery were evaluated...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28073683/mutant-allele-tumor-heterogeneity-scores-correlate-with-risk-of-metastases-in-colon%C3%A2-cancer
#9
Ashwani Rajput, Thèrése Bocklage, Alissa Greenbaum, Ji-Hyun Lee, Scott A Ness
BACKGROUND: Colorectal cancer is a leading cause of cancer-related mortality, has a very broad mutational spectrum, and there is no clinically available biomarker that can predict which patients with stage II or stage III colorectal cancer will develop metastatic disease. PATIENTS AND METHODS: We used a targeted next-generation sequencing approach to analyze the mutational spectra in stage II and III colon cancer patient samples. RESULTS: Amidst a broad range of acquired mutations and variants, we found evidence of tumor heterogeneity that distinguished the tumors in different groups...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28065664/racial-differences-in-stage-iv-colorectal-cancer-survival-in-younger-and-older-patients
#10
Kristin Wallace, Allan DeToma, David N Lewin, Shaoli Sun, Don Rockey, Carolyn D Britten, Jennifer D Wu, Aissatou Ba, Anthony J Alberg, Elizabeth G Hill
INTRODUCTION: African Americans (AAs) compared with European Americans (EAs) have poorer stage-specific survival from colorectal cancer (CRC). Recent reports have indicated that the racial difference in survival has worsened over time, especially among younger patients. To better characterize this association, we used population-based Surveillance, Epidemiology, and End Results registry data to evaluate the effect of race on stage IV CRC survival in patients aged < 50 and ≥ 50 years...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28063788/response-to-chemotherapy-and-prognosis-in-metastatic-colorectal-cancer-with-dna-deficient-mismatch-repair
#11
Alexandra Khichfy Alex, Sheila Siqueira, Renata Coudry, Juliana Santos, Michel Alves, Paulo M Hoff, Rachel P Riechelmann
BACKGROUND: DNA deficient mismatch repair (dMMR) genes are associated with microsatellite instability and good prognosis in early-stage colorectal cancer (CRC). However dMMR is rare in metastatic CRC (mCRC) and little is known about its influence on treatment response rate (RR). The primary objective of this study was to compare the RR of patients with mCRC according to dMMR status. METHODS: This was a retrospective study that compared the RR by Response Evaluation Criteria In Solid Tumors 1...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27979717/perioperative-triplet-chemotherapy-and-cetuximab-in-patients-with-ras-wild-type-high-recurrence-risk-or-borderline-resectable-colorectal-cancer-liver-metastases
#12
Filippo Pietrantonio, Maria Di Bartolomeo, Christian Cotsoglou, Alessia Mennitto, Rosa Berenato, Federica Morano, Jorgelina Coppa, Federica Perrone, Roberto Iacovelli, Massimo Milione, Alessandra Alessi, Marta Vaiani, Ilaria Bossi, Francesca Ricchini, Mauro Scotti, Marta Caporale, Emilio Bajetta, Filippo de Braud, Vincenzo Mazzaferro
BACKGROUND: For borderline resectable colorectal cancer liver metastases (CLM), systemic treatment can help to achieve R0 resection and reduce the risk of relapse. We assessed the role of perioperative triplet chemotherapy in combination with cetuximab in patients with RAS wild type high recurrence risk and/or borderline resectable CLM. PATIENTS AND METHODS: This was a monocenter, open-label phase II study. Borderline resectability was defined technically as tumor involvement of >1 hepatic vein, or >4 hepatic segments, need for 2-stage hepatectomy or radiofrequency ablation, and/or biologically (high risk): ≥4 metastatic nodules, or synchronous metastases...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27856123/prognostic-impact-of-primary-tumor-location-on-clinical-outcomes-of-metastatic-colorectal-cancer-treated-with-cetuximab-plus-oxaliplatin-based-chemotherapy-a-subgroup-analysis-of-the-jaccro-cc-05-06-trials
#13
Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji, Tadamichi Denda, Yoshihiko Segawa, Yuji Negoro, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima
INTRODUCTION: Primary tumor location is a critical prognostic factor in metastatic colorectal cancer (mCRC); however, it remains unclear whether tumor location is a predictor of the response to cetuximab treatment. It is also uncertain if BRAF mutation contributes to the impact of tumor location on survival. We assessed the prognostic impact of tumor location on clinical outcomes in mCRC patients treated with first-line cetuximab chemotherapy. PATIENTS AND METHODS: The associations of tumor location with overall survival and progression-free survival were evaluated in mCRC patients with KRAS exon 2 wild-type tumors who were enrolled onto 2 clinical trials: JACCRO CC-05 of cetuximab plus FOLFOX (n = 57, UMIN000004197) and CC-06 of cetuximab plus SOX (n = 61, UMIN000007022)...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27839727/attitudes-of-patients-with-gastrointestinal-cancers-toward-research-biopsies
#14
Sing Yu Moorcraft, Ruwaida Begum, David Cunningham, Clare Peckitt, Chiara Baratelli, Angela Gillbanks, Penelope Rogers, Vitalis Nwokorie, Ian Chau, David Watkins, Naureen Starling
BACKGROUND: Research biopsies are an increasingly important component of clinical trials, but there are concerns that biopsies may deter patients from participating in research. PATIENTS AND METHODS: Patients participating in a single-center study investigating the feasibility of molecular profiling in advanced gastrointestinal cancers were asked to complete a questionnaire regarding their reasons for consenting/declining optional research biopsies and blood samples...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27810226/the-role-of-cyclooxygenase-2-in-colorectal-carcinogenesis
#15
REVIEW
Yongsong Liu, Hong Sun, Min Hu, Yuan Zhang, Shuangling Chen, Sean Tighe, Yingting Zhu
Colorectal cancer is a major worldwide health care problem that accounts for 1 million new cases each year. The risk factors for this disease include hereditary factors, environmental agents, and inflammatory stimuli that affect the gastrointestinal tract. Among these risk factors, cyclooxygenase-2 (COX-2) is one of the major players in the progression of colorectal cancer; however, the detailed mechanism of its role in causing colorectal cancer is still not well understood. In addition, the role of COX-2 signaling through the interaction in the epithelial and stromal compartments on colorectal carcinogenesis has not been fully illustrated...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27789195/identification-of-high-risk-aberrant-crypt-foci-and-mucin-depleted-foci-in-the-human-colon-with-study-of-colon-cancer-stem-cell-markers
#16
Brijnandan Gupta, Prasenjit Das, Shouriyo Ghosh, Janvie Manhas, Sudip Sen, Sujoy Pal, Peush Sahni, Aashish Dutt Upadhyay, Subrat K Panda, Siddhartha Datta Gupta
BACKGROUND: During colonoscopic screening, only macroscopic lesions will be identified, and these are usually the result of multiple genetic abnormalities. Magnification endoscopic detection of aberrant crypt foci (ACF), long before they acquire complex genetic abnormalities, is promising. However, the features of high-risk ACF-like lesions need to be identified. MATERIALS AND METHODS: In the present cross-sectional study, grossly visible normal mucosal flaps were shaved from 152 colectomies, including 96 colorectal cancer (CRC) cases and 56 controls (22 control specimens with disease with malignant potential and 34 without malignant potential)...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27777043/trends-in-hospitalization-and-mortality-of-venous-thromboembolism-in-hospitalized-patients-with-colon-cancer-and-their-outcomes-us-perspective
#17
Kalpit Devani, Nirav Patil, Carlos Roberto Simons-Linares, Nilay Patel, Palashkumar Jaiswal, Pranav Patel, Samir Patel, Chirag Savani, Kamlesh Sajnani, Mark Young, Chakradhar Reddy
INTRODUCTION: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in hospitalized patients with colon cancer. We assessed nationwide population-based trends in rates of hospitalization and mortality from VTE among patients with colon cancer to determine its impact. METHODS: We queried the Nationwide Inpatient Sample (NIS) database entries from 2003 to 2011 to identify patients with colon cancer. Bivariate group comparisons between hospitalized patients with colon cancer with VTE to those without VTE were made...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27756521/the-course-of-neuropathic-symptoms-in-relation-to-adjuvant-chemotherapy-among-elderly-patients-with-stage-iii-colon-cancer-a%C3%A2-longitudinal-study
#18
Felice N van Erning, Maryska L G Janssen-Heijnen, Johannes A Wegdam, Gerrit D Slooter, Jan H Wijsman, Art Vreugenhil, Tonneke A J M Beijers, Lonneke V van de Poll-Franse, Valery E P P Lemmens
INTRODUCTION: Among the elderly, the impairment of functional capacities due to neuropathy can have a significant impact. The aim of the present study was to investigate the course of neuropathic symptoms among elderly patients with stage III colon cancer treated with CAPOX (capecitabine, oxaliplatin), capecitabine monotherapy, or no adjuvant chemotherapy. MATERIALS AND METHODS: The Netherlands Cancer Registry was used to select patients with stage III colon cancer and aged ≥ 70 years...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27742264/chemotherapy-tolerance-and-oncologic-outcomes-in-patients-with-colorectal-cancer-with-and-without-inflammatory-bowel-disease
#19
Jordan Axelrad, Anuja Kriplani, Umut Ozbek, Noam Harpaz, Jean-Frederic Colombel, Steven Itzkowitz, Randall F Holcombe, Celina Ang
BACKGROUND: Inflammatory bowel disease (IBD), comprising Crohn disease and ulcerative colitis, is a risk factor for colorectal cancer (CRC). Chemotherapy toxicity may exacerbate IBD symptoms and vice versa, but data are limited. We evaluated chemotherapy tolerance and oncologic outcomes in patients with CRC with and without IBD. PATIENTS AND METHODS: Medical records of patients with CRC with and without IBD treated between 2008 and 2013 were reviewed. Where possible, patients were matched by age, sex, stage, and diagnosis year...
September 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27687815/capecitabine-and-oxaliplatin-prior-and-concurrent-to-preoperative-pelvic-radiotherapy-in-patients-with-locally-advanced-rectal-cancer-long-term-outcome
#20
Viviane Hess, Ralph Winterhalder, Roger von Moos, Lucas Widmer, Priska Stocker, Monika Jermann, Richard Herrmann, Dieter Koeberle
BACKGROUND: The risk/benefit ratio of any treatment can only be fully assessed if long-term results of both efficacy and toxicity are taken into account. Whereas the combined modality treatment of locally advanced rectal cancer (LARC) has considerably improved prognosis, particularly with regard to local control, long-term results-including patient-reported outcomes-are underreported. PATIENTS AND METHODS: Patients with LARC treated within a multicenter single-arm phase II study were prospectively assessed for at least 5 years after surgery...
September 2017: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"